REGENXBIO CEO Ken Mills Shines Light on Promising Phase I Trials for Wet AMD Gene Therapy RGX-314

REGENXBIO CEO Ken Mills Shines Light on Promising Phase I Trials for Wet AMD Gene Therapy RGX-314

Episode 190

REGENXBIO founding CEO Ken Mills reviews the company’s recent positive Phase I results for RGX-314, a potentially game-changing gene therapy for wet AMD. Mills also shares the responsibility he feels leading a pioneer in the blockbuster gene therapy field.

Do You Have

A STORY TO TELL?

If you’d like to be considered as a guest on a future episode of the OIS podcast, please complete the application today.

Meet Our Host

TOM SALEMI

Tom-Salemi

Joining the company in 2014, to create and manage a new line of podcasts, publications and other editorial products.

Subscribe

ON iTUNES

Don't miss an episode. Join the conversation by visiting our podcast channel on iTunes today and subscribe. It's fast and free!

STAY UP TO DATE WITH OIS

Get the Latest News, Podcasts and Videos.